Fennec Pharmaceuticals

Compare

24 Followers

FRX Stock Chart & Stats

C$12.33

C$0.03(0.34%)

At close: Jan 08 4:00 PM EST

C$12.33

C$0.03(0.34%)

Day’s Range― - ―

52-Week RangeC$5.65 - C$13.83

Previous CloseN/A

Volume1.30K

Average Volume (3M)664.00

Market Cap

$352.63M

Enterprise ValueC$311.49M

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta1.44

Next Earnings

Nov 06, 2025

EPS Estimate

-0.03

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.15

Shares Outstanding27,831,697

10 Day Avg. Volume531

30 Day Avg. Volume664

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.88

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$19.23

Price Target Upside55.95% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

International ExpansionEuropean and international advancement continuing with the acceptance of PEDMARQSI® by the Scottish Medicines Consortium (SMC) for use in Scotland.

Product AdoptionA large national oncology group has added PEDMARK to its formulary for patients under 40 years of age, signaling momentum for broader adoption in community settings.

Regulatory EndorsementsPEDMARK is recommended for the adolescent and young adult (AYA) population by the National Comprehensive Cancer Network (NCCN) with a 2A endorsement.

Bears Say

Fennec Pharmaceuticals News

Fennec Pharmaceuticals Reports Strong Growth in Earnings Call

Fennec Pharmaceuticals (($TSE:FRX)) has held its Q2 earnings call. Read on for the main highlights of the call....

2M ago

FENC

Fennec Pharmaceuticals: Strategic Advancements and Market Expansion Justify Buy Rating

Fennec Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from...

2M ago

FENC

Fennec Pharmaceuticals’ Promising Growth and Market Potential Drive Buy Rating

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Fennec Pharmaceuticals, with a price target of...

2M ago

FENC

Fennec Pharmaceuticals Reports Strong Q2 2025 Results and Expands Global Reach

Fennec Pharmaceuticals ( ($TSE:FRX) ) has provided an announcement. Fennec Pharmaceuticals reported a strong second quarter in 2025,...

2M ago

FENC

Fennec price target raised to $14 from $13 at Craig-Hallum

Craig-Hallum analyst Chase Knickerbocker raised the firm’s price target on Fennec (FENC) to $14 from $13 and keeps...

3M ago

FENC

Fennec Pharmaceuticals Reports Strong Q2 2025 Growth

Fennec Pharmaceuticals ( ($FENC) ) has released its Q2 earnings. Here is a breakdown of the information Fennec...

3M ago

FENC

Fennec Pharmaceuticals trading resumes

09:38 EDT Fennec (FENC) Pharmaceuticals trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

3M ago

FENC

Fennec Pharmaceuticals trading halted, volatility trading pause

09:33 EDT Fennec (FENC) Pharmaceuticals trading halted, volatility trading pause Published first on TheFly – the ultimate source...

3M ago

FENC

Fennec Pharmaceuticals Sees Strong Q2 Growth and Expands Global Reach

Fennec Pharmaceuticals ( ($TSE:FRX) ) has shared an update. Fennec Pharmaceuticals reported a strong second quarter of 2025...

3M ago

FENC

Fennec reports Q2 EPS (11c), consensus (3c)

Reports Q2 revenue $9.7M, consensus $9.56M. “We are pleased to have delivered three consecutive quarters of strong performance,...

3M ago

FENC

FENC Upcoming Earnings Report: What to Expect?

Fennec Pharmaceuticals (FENC) is scheduled to report 2nd quarter earnings on 08/14/2025, before the market opens. Regarding Q2...

3M ago

FENC

Fennec Pharmaceuticals to Announce Q2 2025 Financial Results

Fennec Pharmaceuticals ( ($TSE:FRX) ) has provided an announcement. Fennec Pharmaceuticals announced it will release its second quarter...

3M ago

FENC

Fennec Pharmaceuticals Approves Proposals at Shareholder Meeting

The latest update is out from Fennec Pharmaceuticals ( ($TSE:FRX) ). On June 3, 2025, Fennec Pharmaceuticals Inc....

5M ago

FENC

Fennec management to meet with Craig-Hallum

Meeting to be held in Toronto on June 4 hosted by Craig-Hallum. Published first on TheFly – the...

5M ago

FENC

FRX FAQ

What was Fennec Pharmaceuticals’s price range in the past 12 months?

Fennec Pharmaceuticals lowest stock price was C$5.65 and its highest was C$13.83 in the past 12 months.

What is Fennec Pharmaceuticals’s market cap?

Fennec Pharmaceuticals’s market cap is $352.63M.

When is Fennec Pharmaceuticals’s upcoming earnings report date?

Fennec Pharmaceuticals’s upcoming earnings report date is Nov 06, 2025 which is in 8 days.

How were Fennec Pharmaceuticals’s earnings last quarter?

Fennec Pharmaceuticals released its earnings results on Aug 14, 2025. The company reported -C$0.152 earnings per share for the quarter, missing the consensus estimate of -C$0.047 by -C$0.105.

Is Fennec Pharmaceuticals overvalued?

According to Wall Street analysts Fennec Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Fennec Pharmaceuticals pay dividends?

Fennec Pharmaceuticals does not currently pay dividends.

What is Fennec Pharmaceuticals’s EPS estimate?

Fennec Pharmaceuticals’s EPS estimate is -0.03.

How many shares outstanding does Fennec Pharmaceuticals have?

Fennec Pharmaceuticals has 27,831,697 shares outstanding.

What happened to Fennec Pharmaceuticals’s price movement after its last earnings report?

Fennec Pharmaceuticals reported an EPS of -C$0.152 in its last earnings report, missing expectations of -C$0.047. Following the earnings report the stock price went down -9.193%.

Which hedge fund is a major shareholder of Fennec Pharmaceuticals?

Currently, no hedge funds are holding shares in TSE:FRX

Fennec Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-28.95%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc. (FRX) is a biopharmaceutical company focused on the development and commercialization of innovative cancer treatments. The company operates primarily in the biotechnology sector and is dedicated to addressing the critical needs of cancer patients, particularly in the area of pediatric oncology. Its flagship product, PEDMARK, is designed to prevent ototoxicity, which is hearing loss caused by platinum-based chemotherapy treatments in children.

Fennec Pharmaceuticals (FRX) Earnings & Revenues

Historic Earnings Reports

FRX Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The call highlighted strong revenue growth and market adoption for PEDMARK, supported by strategic expansions and new accounts. However, increased operating expenses and dependency on market expansion present challenges. The momentum in PEDMARK's adoption and international expansion efforts suggest positive future prospects.View all TSE:FRX earnings summaries

FRX Stock 12 Month Forecast

Average Price Target

C$19.23

▲(55.95% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"C$5","9":"C$9","13":"C$13","17":"C$17","21":"C$21"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20.97690855,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$20.98</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.2288328375,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$19.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.17998741,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$18.18</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,9,13,17,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.99,13.604377580769231,14.218755161538462,14.833132742307694,15.447510323076923,16.061887903846156,16.676265484615385,17.290643065384614,17.905020646153847,18.51939822692308,19.13377580769231,19.74815338846154,20.36253096923077,{"y":20.97690855,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.99,13.46991021826923,13.949820436538461,14.429730654807692,14.909640873076924,15.389551091346155,15.869461309615385,16.349371527884614,16.829281746153846,17.30919196442308,17.789102182692307,18.26901240096154,18.74892261923077,{"y":19.2288328375,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.99,13.38922980076923,13.788459601538461,14.187689402307692,14.586919203076922,14.986149003846153,15.385378804615385,15.784608605384616,16.183838406153846,16.583068206923077,16.982298007692307,17.381527808461538,17.78075760923077,{"y":18.17998741,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.505,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.23,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.64,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.56,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.08,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.81,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.805,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.14,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.21,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.55,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.01,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.99,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >